title: C-terminal peptide of anaphylatoxin C3a enhances hepatic function after steatotic liver transplantation: a study in a rat model.
abstract: BACKGROUND
  C3a, a complement component stimulates hepatocyte proliferation. In this study, we investigated whether a functional peptide from its C terminal, YAAALGLAR (C3aP), enhanced liver function after steatotic liver transplantation in a rat model.
  
  
  METHODS
  Livers of Sprague-Dawley (SD) rats fed a high-fat diet for 2 months were used as donors. Their liver parenchyma displayed over 60% macrovesicular steatosis upon histopathologic examination. Weight and age-matched isogeneic SD rats were used as recipients of orthotopic liver transplantations (OLTs). Before OLT, the donor livers were perfused with University of Wisconsin solution supplemented with 10 mg/L C3aP. Postoperatively, 0.1 mL of 100 microg/mL C3aP was administered daily intraperitoneally to the experimental group. Recipients without C3aP intraperitoneal administration were the control group. We examined the survival rates, histopathologic changes, and hepatic functions of recipients.
  
  
  RESULTS
  Six of the 10 control recipients died within 3 days posttransplantation; however, among the experimental group, 8 of 10 recipients survived beyond 7 days. Histopathologic examination showed that at day 3 posttransplantation, hepatocyte steatosis was notably reversed in the experimental group with cells undergoing active mitosis. In contrast, massive parenchymal necrosis was observed among the control group without notable hepatocyte proliferation. Furthermore, serum enzyme levels among the experimental group were significantly lower than those of the control group at day 3 postoperatively.
  
  
  CONCLUSIONS
  C3aP stimulated hepatocyte proliferation and reversed fatty degradation of hepatocytes, thus enhancing hepatic function and prolonging the survival of recipients of steatotic liver transplantations.
authors.affiliation: Department of Geriatrics, Chengdu Military General Hospital, Chengdu, China.
authors.forename: X H
authors.initials: XH
authors.lastname: Xu
authors.forename: H S
authors.initials: HS
authors.lastname: Peng
authors.forename: M Q
authors.initials: MQ
authors.lastname: Sun
authors.forename: M
authors.initials: M
authors.lastname: Hu
authors.forename: R
authors.initials: R
authors.lastname: Zhang
authors.forename: W H
authors.initials: WH
authors.lastname: Wang
authors.forename: X Y
authors.initials: XY
authors.lastname: He
authors.forename: X R
authors.initials: XR
authors.lastname: Xiao
mesh_terms: D000706:Anaphylatoxins / Q000627:therapeutic use; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D015926:Complement C3a / Q000737:chemistry* / Q000627:therapeutic use*; D004041:Dietary Fats; D005234:Fatty Liver / Q000473:pathology* / Q000601:surgery; D008115:Liver Regeneration; D016031:Liver Transplantation / Q000401:mortality / Q000473:pathology / Q000502:physiology*; D008297:Male; D010446:Peptide Fragments / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D016019:Survival Analysis
chemical_list: D000706:Anaphylatoxins; D004041:Dietary Fats; D010446:Peptide Fragments; D015926:Complement C3a; D001219:Aspartate Aminotransferases